Carna Biosciences will close our operation from April 29 (Wed) through May 6 (Wed), 2026 for National holidays in Japan. Our normal business will be resumed on May 7, 2026, and all the messages received and orders placed within the holiday period will be dealt with and/or answered back right after that.
Our subsidiary in the U.S.A.and all our distributors outside of Japan will remain open business as usual.
We regret any inconveniences this might cause to our valued customers.

Five pseudokinases have been newly released！
Pseudokinases are proteins that structurally resemble kinases but lack the amino acid residues essential for catalytic phosphorylation activity, rendering them enzymatically inactive. They account for approximately 10% of the entire human kinome.
Their implication in a broad spectrum of diseases underscores their potential as therapeutic targets, paving the way for innovative treatment strategies that circumvent traditional reliance on enzymatic activity.
Carna's pseudokinases are available as biotinylated proteins for versatile applications across a wide range of research and development needs.

Cat#    02-477-20N        BTN-CASK
Cat#    08-450-20C         BTN-JAK1(JH2)
Cat#    14-401-20N         BTN-PAN3
Cat#    08-488-20N         BTN-ROR2
Cat#    07-431-20C         BTN-STRADA

Carna's Biotinylated Proteins, which are biologically labeled with a single biotin molecule at the N- or C- terminus, are useful not only for affinity measurements to evaluate interactions between molecules, but also for a wide range of other applications. Please try them out!